Terms: = Lung cancer AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721
2218 results:
1. Downregulation of lncRNA MIR17HG reduced tumorigenicity and Treg-mediated immune escape of non-small-cell lung cancer cells through targeting the miR-17-5p/RUNX3 axis.
Zheng G; Ye H; Bai J; Zhang X
J Biochem Mol Toxicol; 2024 May; 38(5):e23715. PubMed ID: 38704830
[TBL] [Abstract] [Full Text] [Related]
2. HBB as a Novel Biomarker for the Diagnosis and Monitoring of lung cancer Regulates Cell Proliferation via ERK1/2 Pathway.
Xu X; Cai H; Peng J; Liu H; Chu F
Technol Cancer Res Treat; 2024; 23():15330338241249032. PubMed ID: 38679728
[No Abstract] [Full Text] [Related]
3. RACGAP1 promotes lung cancer cell proliferation through the PI3K/AKT signaling pathway.
Xu Z; Wu S; Tu J; Wang M; Liang W; Cheng J; Guan J; Xu J
Sci Rep; 2024 Apr; 14(1):8694. PubMed ID: 38622149
[TBL] [Abstract] [Full Text] [Related]
4. LncRNA MIR100HG affects the proliferation and metastasis of lung cancer cells through mediating the microRNA-5590-3p/DCBLD2 axis.
Min S; Zhang L; Zhang L; Liu F; Liu M
Immun Inflamm Dis; 2024 Apr; 12(4):e1223. PubMed ID: 38602284
[TBL] [Abstract] [Full Text] [Related]
5. [High LINC00626 expression promotes esophagogastric junction adenocarcinoma metastasis: the mediating role of the JAK1/STAT3/KHSRP axis].
Zhang F; Fan L; Kang X; Wei H; Li L
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Mar; 44(3):541-552. PubMed ID: 38597446
[TBL] [Abstract] [Full Text] [Related]
6. NPAS2, transcriptionally activated by ARRB1, promotes the malignant behaviours of lung adenocarcinoma cells and regulates the reprogramming of glucose metabolism.
Wang S; Huang C; Zheng Y; Wu X; Zhong Y
Clin Exp Pharmacol Physiol; 2024 May; 51(5):e13860. PubMed ID: 38584327
[TBL] [Abstract] [Full Text] [Related]
7. Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1.
Li J; Ma X; Xu F; Yan Y; Chen W
Pharm Biol; 2024 Dec; 62(1):314-325. PubMed ID: 38571483
[TBL] [Abstract] [Full Text] [Related]
8. Silencing of circ_0088036 inhibits growth and invasion of lung adenocarcinoma through miR-203/SP1 axis.
Liu X; Feng Y; Wang L; Shi L; Ji K; Hu N; Du Y; Liu M; Wang M
J Biochem Mol Toxicol; 2024 Apr; 38(4):e23684. PubMed ID: 38533528
[TBL] [Abstract] [Full Text] [Related]
9. If it's a target, it's a pan-cancer target: Tissue is not the issue.
Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
[TBL] [Abstract] [Full Text] [Related]
10. Polyphyllin I enhances tumor necrosis factor-related apoptosis-inducing ligand-induced inhibition of human osteosarcoma cell growth downregulating the Wnt/β-catenin pathway.
Junli C; Fulai Z; Xingyuan S; Xiaoping MA; Peng Z; Chujie Z; Binhao S; Wenchao GU; Yongjun W; Yanping Y
J Tradit Chin Med; 2024 Apr; 44(2):251-259. PubMed ID: 38504531
[TBL] [Abstract] [Full Text] [Related]
11. USP3 promotes cisplatin resistance in non-small cell lung cancer cells by suppressing ACOT7-regulated ferroptosis.
Tao R; Liu Z; Zhang Z; Zhang Z
Anticancer Drugs; 2024 Jul; 35(6):483-491. PubMed ID: 38502867
[TBL] [Abstract] [Full Text] [Related]
12. Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors.
Morelli M; Carbone ML; Scaglione GL; Scarponi C; Di Francesco V; Pallotta S; De Galitiis F; Rahimi S; Madonna S; Failla CM; Albanesi C
Front Immunol; 2024; 15():1346687. PubMed ID: 38495872
[TBL] [Abstract] [Full Text] [Related]
13. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell lung cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway.
Wang L; Xu L; Han S; Zhu X
Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
[TBL] [Abstract] [Full Text] [Related]
14. METTL3-mediated the m6A modification of SF3B4 facilitates the development of non-small cell lung cancer by enhancing LSM4 expression.
He G; Gu K; Wei J; Zhang J
Thorac Cancer; 2024 Apr; 15(11):919-928. PubMed ID: 38462740
[TBL] [Abstract] [Full Text] [Related]
15. RNF135 promotes cell proliferation and autophagy in lung adenocarcinoma by promoting the phosphorylation of ULK1.
Zhuang L; Shi G; Sun Y
Allergol Immunopathol (Madr); 2024; 52(2):3-9. PubMed ID: 38459884
[TBL] [Abstract] [Full Text] [Related]
16. PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast cancer by Activating Notch Signaling.
Li B; Huang L; Ruan J
Rev Invest Clin; 2024; 76(1):45-59. PubMed ID: 38442372
[TBL] [Abstract] [Full Text] [Related]
17. β-Sitosterol attenuates anlotinib resistance in non-small cell lung cancer cells by inhibiting miR-181a-3p/SHQ1 signaling.
Wang LH; Sun YH; Liu H; Yang X; Wen Z; Tian XF
Chem Biol Drug Des; 2024 Mar; 103(3):e14493. PubMed ID: 38439529
[TBL] [Abstract] [Full Text] [Related]
18. Humoral immune response to tumor-associated antigen Ubiquilin 1 (UBQLN1) and its tumor-promoting potential in lung cancer.
Wang Y; Ouyang S; Liu M; Si Q; Zhang X; Zhang X; Li J; Wang P; Ye H; Shi J; Song C; Wang K; Dai L
BMC Cancer; 2024 Mar; 24(1):283. PubMed ID: 38431566
[TBL] [Abstract] [Full Text] [Related]
19. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach.
Nielsen LR; Stensgaard S; Meldgaard P; Sorensen BS
Cancer Treat Res Commun; 2024; 39():100802. PubMed ID: 38428066
[TBL] [Abstract] [Full Text] [Related]
20. Influence of
Li Y; Cui WW; Yang ZF; Liu WH; Bian MW; Deng J; Wang T
Chin Med Sci J; 2024 Mar; 39(1):9-18. PubMed ID: 38426412
[TBL] [Abstract] [Full Text] [Related]
[Next]